Jun 2026 (Q2 FY26) — Aug 13, 2026
CorMedix Q2 FY26 — Strong Financials and Pipeline Progress
Read the full callCorMedix (CRMD) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
CorMedix earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 102 | +156.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 42.1 | −7.1 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 26.0 | +31.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$7.38 +1.65% · +$0.12
Performance −27.5% 1Y
1Y: $10.18 on 17 Oct 2025 → $7.38. High $12.73 (29 Dec 2025), low $6.25 (20 Mar 2026).
- Previous close
- $7.26
- 52-week range
- $6.25 – $12.73
- One year
- −39.31%
Overview
- Symbol
- CRMD
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
CorMedix earnings calls (CRMD)
Financials
What the filings say
Net profit, year on year: +31% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 11 | 31 | 39 | 40 | 104 | 129 | 127 | 102 |
| Operating profit | -3 | 13 | 20 | 20 | 51 | 59 | 64 | 43 |
| Operating margin | −28.7% | 41.5% | 51.5% | 49.2% | 49.2% | 46.0% | 50.0% | 42.1% |
| Other income | 1 | 1 | 1 | 1 | 1 | -3 | -8 | -4 |
| Interest | 0 | 0 | 0 | 0 | 1 | 2 | — | — |
| Profit before tax | -3 | 13 | 21 | 20 | 53 | 56 | 56 | 39 |
| Tax rate | — | 0.0% | 0.0% | 2.6% | −106.5% | 75.2% | 30.6% | 32.9% |
| Net profit | -3 | 13 | 21 | 20 | 109 | 14 | 39 | 26 |
| EPS ($ per share) | -0.05 | — | 0.32 | 0.29 | 1.42 | — | 0.48 | 0.33 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -179 | -195 | -217 | -246 | -275 | -322 | -340 | -177 |
| Total liabilities | 14 | 6 | 5 | 6 | 7 | 12 | 34 | 421 |
| Fixed assets | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 6 |
| Investments | 0 | 12 | 4 | 12 | 16 | 32 | 11 | 10 |
| Total assets | 19 | 29 | 49 | 69 | 62 | 82 | 119 | 826 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -24 | -15 | -22 | -21 | -24 | -38 | -51 | 175 |
| Cash from investing | 2 | -12 | 7 | -9 | -4 | -17 | 21 | -308 |
| Cash from financing | 29 | 26 | 40 | 42 | 18 | 56 | 26 | 238 |
| Net cash flow | — | -1 | 26 | 11 | -10 | 0 | -3 | 105 |
| Capital expenditure | -0 | -0 | -0 | -1 | -0 | -0 | -0 | -2 |
| Free cash flow | -24 | -15 | -22 | -23 | -25 | -39 | -51 | 173 |
Insider filings
49 filings between Oct 23, 2025 and Sep 18, 2026.
Open market
decisions to buy or sellPurchases
$275.5K
1 purchase by 1 insider
Sales
$2.64M
8 sales by 4 insiders
63% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 14
- Award — granted as compensation
- 14
- Option exercise — converted options into shares
- 12
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Dillione Janet | — | $1.55M | Jan 21, 2026 |
| Lefkowitz Steven W | — | $475.2K | Dec 9, 2025 |
| Todisco Joseph | — | $360.0K | Dec 18, 2025 |
| Kaplan Myron | $275.5K | — | Oct 23, 2025 |
| DUNTON ALAN W | — | $260.0K | Dec 30, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 18, 2026 | Dillione Janet Director | Option exercise | 48,909 | — |
| Aug 29, 2026 | Hurlburt Elizabeth Chief Operating Officer | Tax withheld | 8,076 | $67.0K |
| Aug 29, 2026 | Zelnick Kaufman Beth Chief Legal Officer | Tax withheld | 8,424 | $69.9K |
| Aug 29, 2026 | Blum Susan Chief Financial Officer | Tax withheld | 8,424 | $69.9K |
| Feb 4, 2026 | Todisco Joseph Chief Executive Officer | Award | 77,156 | $0 |
| Feb 4, 2026 | Hurlburt Elizabeth Chief Operating Officer | Award | 36,006 | $0 |
| Feb 4, 2026 | Zelnick Kaufman Beth Chief Legal Officer | Award | 36,006 | $0 |
| Jan 26, 2026 | Dillione Janet Director | Award | 30,453 | $0 |
| Jan 26, 2026 | Duncan Gregory Scott Director | Award | 30,453 | $0 |
| Jan 26, 2026 | Kaplan Myron Director | Award | 30,453 | $0 |
| Jan 26, 2026 | Lefkowitz Steven W Director | Award | 30,453 | $0 |
| Jan 26, 2026 | DUNTON ALAN W Director | Award | 30,453 | $0 |
| Jan 26, 2026 | Stewart Robert A Director | Award | 30,453 | $0 |
| Jan 23, 2026 | Zelnick Kaufman Beth Chief Legal Officer | Award | 72,820 | $0 |
| Jan 23, 2026 | Todisco Joseph Chief Executive Officer | Award | 225,900 | $0 |
| Jan 23, 2026 | Todisco Joseph Chief Executive Officer | Tax withheld | 27,306 | $198.5K |
| Jan 23, 2026 | Hurlburt Elizabeth Chief Operating Officer | Award | 93,010 | $0 |
| Jan 23, 2026 | Hurlburt Elizabeth Chief Operating Officer | Tax withheld | 10,778 | $78.4K |
| Jan 23, 2026 | Blum Susan Chief Financial Officer | Tax withheld | 9,767 | $71.0K |
| Jan 23, 2026 | Blum Susan Chief Financial Officer | Award | 72,820 | $0 |
| Jan 23, 2026 | Zelnick Kaufman Beth Chief Legal Officer | Tax withheld | 8,803 | $64.0K |
| Jan 21, 2026 | Dillione Janet Director | Sale 10b5-1 plan | 10,000 | $68.8K |
| Jan 17, 2026 | Todisco Joseph Chief Executive Officer | Tax withheld | 22,665 | $153.7K |
| Jan 16, 2026 | Todisco Joseph Chief Executive Officer | Option exercise | 29,585 | $100.0K |
| Jan 12, 2026 | Hurlburt Elizabeth Chief Operating Officer | Tax withheld | 5,794 | $41.4K |
| Jan 12, 2026 | Todisco Joseph Chief Executive Officer | Tax withheld | 17,417 | $124.5K |
| Jan 12, 2026 | Lefkowitz Steven W Director | Option exercise | 15,000 | $84.5K |
| Jan 8, 2026 | Seckler Michael David Chief Commercial Officer | Award | 133,156 | $0 |
| Jan 2, 2026 | Zelnick Kaufman Beth Chief Legal Officer | Tax withheld | 11,333 | $137.8K |
| Jan 2, 2026 | Hurlburt Elizabeth Chief Operating Officer | Tax withheld | 10,895 | $132.5K |
| Dec 30, 2025 | DUNTON ALAN W Director | Option exercise 10b5-1 plan | 20,000 | $80.6K |
| Dec 30, 2025 | DUNTON ALAN W Director | Sale 10b5-1 plan | 20,000 | $260.0K |
| Dec 18, 2025 | Todisco Joseph Chief Executive Officer | Option exercise 10b5-1 plan | 30,000 | $132.9K |
| Dec 18, 2025 | Todisco Joseph Chief Executive Officer | Sale 10b5-1 plan | 30,000 | $360.0K |
| Dec 9, 2025 | Dillione Janet Director | Option exercise 10b5-1 plan | 19,000 | $181.4K |
| Dec 9, 2025 | Dillione Janet Director | Option exercise 10b5-1 plan | 15,000 | $84.5K |
| Dec 9, 2025 | Dillione Janet Director | Sale 10b5-1 plan | 34,000 | $408.0K |
| Dec 9, 2025 | Lefkowitz Steven W Director | Sale | 40,000 | $475.2K |
| Dec 2, 2025 | Dillione Janet Director | Option exercise 10b5-1 plan | 12,210 | $49.2K |
| Dec 2, 2025 | Dillione Janet Director | Sale 10b5-1 plan | 46,657 | $466.6K |
| Dec 2, 2025 | Dillione Janet Director | Option exercise 10b5-1 plan | 19,323 | $68.6K |
| Dec 2, 2025 | Dillione Janet Director | Option exercise 10b5-1 plan | 15,124 | $67.0K |
| Nov 24, 2025 | Dillione Janet Director | Option exercise | 4,876 | $21.6K |
| Nov 24, 2025 | Dillione Janet Director | Option exercise | 5,677 | $20.2K |
| Nov 24, 2025 | Dillione Janet Director | Option exercise | 8,000 | $22.8K |
| Nov 24, 2025 | Dillione Janet Director | Option exercise | 7,790 | $31.4K |
| Nov 24, 2025 | Dillione Janet Director | Sale | 26,343 | $261.6K |
| Nov 14, 2025 | Dillione Janet Director | Sale | 30,000 | $342.6K |
| Oct 23, 2025 | Kaplan Myron Director | Purchase | 25,000 | $275.5K |
| Sep 16, 2025 | Duncan Gregory Scott Director | Option exercise | 13,333 | $110.9K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for CorMedix Inc.
Free account. Everything above stays public.
Write why you follow CorMedix Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading